Phase 1/2 study of weekly paclitaxel with or without alisertib, an investigational aurora a kinase inhibitor: Phase 1 results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer
Saved in:
| Title: | Phase 1/2 study of weekly paclitaxel with or without alisertib, an investigational aurora a kinase inhibitor: Phase 1 results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer |
|---|---|
| Authors: | Falchook, G.1, Goff, B.2, Kurzrock, R.1, Gray, H.2, Martin, L.3, Coleman, R.1, Xiao, H.4, Zhou, X.4, Benaim, E.4, Schilder, R.5 |
| Source: | Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS31-S32. 0p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00908258 |
|---|---|
| DOI: | 10.1016/j.ygyno.2011.12.071 |
